Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOMERVILLE, Mass., Sept. 07, 2021 – Finch Therapeutics Group (Nasdaq: FNCH) announced that CEO Mark Smith, PhD, will present an overview at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The on-demand presentation will be accessible on September 13 at 7:00 am ET on Finch's website. Finch Therapeutics specializes in microbiome therapeutics and has a pipeline including CP101, which targets recurrent C. difficile infections and has received FDA Breakthrough Therapy designation.
- None.
- None.
SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available on Monday, September 13, 2021 at 7:00 am ET.
A webcast of the presentation will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. PRISM4, a Phase 3 trial, is designed to serve as the second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Laurence Watts
Gilmartin Group
(619) 916-7620
laurence@gilmartinir.com
or
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
jurban@berrypr.com
212-253-8881
FAQ
When will Finch Therapeutics present at the H.C. Wainwright Conference?
What is the significance of CP101 for Finch Therapeutics?
Where can I watch the Finch Therapeutics presentation?
What types of therapies does Finch Therapeutics develop?
What partnership is Finch Therapeutics involved in?
